Biogen, Inc. has been on the hunt during the past few years for outside assets that can help diversify its largely neurology-focused portfolio, and CEO Chris Viehbacher has been adamant that the company should pursue opportunities in adjacent areas where it has experience, such as immunology and rare diseases. The acquisition of Human Immunology Biosciences, Inc. (HI-Bio) for $1.15bn up front announced on 22 May checks both therapeutic area boxes.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?